Gadolinium MRI Contrast: What Retention Means, What Regulators Decided, and Questions to Ask Before a Scan

In 2017, actor Chuck Norris and his wife Gena made national headlines when they said a common medical procedure nearly killed her. Gena Norris had received several MRI scans with gadolinium-based contrast agents, dyes injected to make images clearer, and said she developed burning pain, weakness, and other debilitating symptoms afterward. The couple sued the manufacturers, and the case drew attention to a question scientists had begun studying only a few years earlier: what happens to gadolinium that stays in the body after an MRI?

Gadolinium contrast is used in tens of millions of MRI scans worldwide each year and helps doctors detect tumors, inflammation, and blood vessel problems. This article explains what is known about gadolinium retention, what regulators decided, what remains uncertain about symptoms some patients report, and what questions patients can ask before a contrast-enhanced MRI.

Is gadolinium MRI contrast dye safe? For most people, yes. Gadolinium-based contrast agents are used in millions of MRI scans and are generally safe, though small amounts can remain in the body (mainly the brain and bones) for a time. Serious harm is rare, mostly affecting people with severe kidney disease. “Gadolinium deposition disease” is debated and not a recognized diagnosis, but newer, more stable agents reduce retention.

What Is Gadolinium MRI Contrast?

Gadolinium-based contrast agents are dyes injected during some MRI scans to make certain tissues, blood vessels, and abnormalities show up more clearly, improving diagnosis. Gadolinium is a rare earth metal with magnetic properties that brighten certain tissues on MRI images. Free gadolinium is toxic, so in contrast agents it is tightly bound to a carrier molecule called a chelate, designed to be excreted by the kidneys within hours or days. Gadolinium-based contrast agents (GBCAs) have been used since the late 1980s and are among the most widely used drugs in medical imaging. They improve the detection of tumors, multiple sclerosis lesions, infections, blood vessel disease, and other conditions.

GBCAs come in two main structural types. In linear agents, the chelate wraps around gadolinium in an open chain; in macrocyclic agents, gadolinium sits inside a cage-like ring, which holds it more tightly. This structural difference turned out to matter for how much gadolinium stays in the body.

Does Gadolinium Stay in the Body?

Research since 2017 confirmed that small amounts of gadolinium can be retained in the brain, bones, and other tissues after scans, though for most people this has not been linked to proven health harm. In 2014, Japanese researchers led by Tomonori Kanda reported in Radiology that patients who had received multiple doses of a gadolinium-based contrast agent showed increasing brightness in specific brain regions, the dentate nucleus and globus pallidus, on MRI scans taken without contrast, and that this signal increased with cumulative dose. The finding suggested gadolinium was accumulating in the brain.

Confirmation came from tissue studies. A 2015 Mayo Clinic study in Radiology by Robert McDonald and colleagues compared brain tissue at autopsy from 13 patients who had undergone at least four gadolinium-enhanced brain MRIs with tissue from 10 patients who had never received gadolinium. All control samples had undetectable gadolinium, while patients in the contrast group had measurable gadolinium deposits in several brain regions, with amounts related to dose. All patients in the contrast group had relatively normal kidney function, showing that retention is not limited to people with kidney disease. Later studies found gadolinium in bone, skin, and other tissues as well.

How Regulators Responded

In July 2017, after reviewing the evidence, the European Medicines Agency recommended suspending the marketing authorizations of several intravenous linear gadolinium agents, while allowing some linear agents for specific uses, such as liver imaging, and continuing to allow macrocyclic agents at the lowest effective dose. The agency found no evidence of harm from brain deposits but acted as a precaution given the greater retention associated with linear agents.

In the United States, the FDA’s Medical Imaging Drugs Advisory Committee met in September 2017 and voted to recommend label changes warning that gadolinium can be retained in organs and tissues, more so with linear agents. As the Bangor Daily News reported, the FDA had said earlier that year that it had found no evidence that brain deposits caused health problems. In December 2017, the FDA required a new class warning for all GBCAs about gadolinium retention and a Medication Guide that patients receive before their first contrast-enhanced MRI, and asked health professionals to consider retention characteristics when choosing an agent, especially for patients who may be at higher risk, such as those needing multiple lifetime doses, pregnant women, children, and people with inflammatory conditions.

Nephrogenic Systemic Fibrosis: A Different, Established Risk

Before retention in healthy people was recognized, gadolinium was linked to a serious disease in people with severe kidney failure. In 2006, Thomas Grobner reported in Nephrology Dialysis Transplantation that patients on dialysis developed nephrogenic systemic fibrosis, a condition causing thickening and hardening of the skin and internal organs, after receiving gadolinium contrast. Subsequent research confirmed the link, particularly with certain linear agents. Regulators added boxed warnings, and radiology practices began screening kidney function and choosing lower-risk agents for patients with kidney disease. Since these changes, new cases of nephrogenic systemic fibrosis have become very rare.

Issue	Who is affected	Strength of evidence
Nephrogenic systemic fibrosis	People with severe kidney disease, mainly after certain linear agents	Established causal link; now rare with precautions
Gadolinium retention in tissues	Anyone receiving GBCAs; more with linear agents and repeated doses	Well documented; clinical significance uncertain
Symptoms attributed to gadolinium	Some patients with normal kidney function report pain, fatigue, skin changes	Reported in case series; causation not established
Acute reactions	Rare allergic-like reactions during or after injection	Well documented; usually mild; serious reactions rare

Is “Gadolinium Deposition Disease” Real?

“Gadolinium deposition disease” is a proposed cluster of symptoms in people with normal kidneys, but it is not an officially recognized diagnosis, and whether retained gadolinium causes these symptoms remains scientifically debated. Some patients with normal kidney function report new symptoms beginning hours to weeks after gadolinium exposure, including burning pain, skin changes, muscle twitching, brain fog, and fatigue. Some physicians and patient advocates have proposed the term “gadolinium deposition disease” for this pattern. The evidence so far comes mainly from surveys and case series, which cannot establish causation because the symptoms are common and nonspecific, and because patients who received MRIs often have underlying conditions that could explain them. Regulators have concluded that current evidence does not show that gadolinium retention causes such symptoms in people with normal kidney function, while acknowledging that research continues.

Gena Norris described receiving three contrast-enhanced MRI scans over eight days and then developing severe symptoms requiring hospitalizations. The Norrises filed suit in November 2017 in San Francisco against 11 manufacturers and distributors, seeking more than $10 million. According to the legal publisher HarrisMartin, the couple later abandoned the lawsuit, which had been inactive since July 2018. Other lawsuits over gadolinium symptoms have been filed in the United States, with mixed outcomes.

How Contrast-Enhanced MRI Works

MRI uses strong magnetic fields and radio waves to create detailed images of the body without ionizing radiation. Some conditions are visible on MRI without contrast, but others, such as certain tumors, inflammation, infections, and blood vessel abnormalities, are easier to detect when a contrast agent changes how nearby tissues appear. Gadolinium shortens the time it takes for hydrogen atoms in tissues to realign with the magnetic field, making areas where contrast accumulates appear brighter on certain image types. Contrast is usually injected into a vein during the scan, and in people with healthy kidneys, most of the agent is eliminated in urine within a day.

Contrast-enhanced MRI is widely used in evaluating brain tumors, multiple sclerosis, spinal disorders, breast cancer screening in high-risk women, heart conditions, liver lesions, and many other conditions. For these uses, contrast often provides information that cannot be obtained otherwise.

What Research Has Found Since 2017

Since regulators acted in 2017, research has continued on several fronts. Imaging and tissue studies have confirmed that macrocyclic agents leave less gadolinium in the brain than linear agents, though small amounts can still be detected after repeated doses. Animal studies have examined whether retained gadolinium affects behavior or tissue function, generally finding no clear harms at clinically relevant doses, though some studies report subtle changes. Large population studies have looked for links between gadolinium exposure and neurological outcomes such as Parkinson’s disease, with most finding no clear association. Researchers continue to study the chemical form of retained gadolinium, how long it stays, and whether certain groups, such as children or people with frequent exposure, could be more susceptible.

Gadolinium in the Environment

Because gadolinium contrast agents are excreted in urine and not fully removed by wastewater treatment, researchers have detected so-called anthropogenic gadolinium in rivers, lakes, and even tap water in some cities with high MRI use. Levels found so far are very low, and health risks from environmental exposure are considered minimal, but the findings have prompted interest in collecting patient urine after MRI and in improving wastewater treatment, illustrating how medical substances can enter the wider environment.

What Is the Difference Between Linear and Macrocyclic Agents?

Linear gadolinium agents release more gadolinium and cause more retention, so regulators restricted some of them; macrocyclic agents hold gadolinium more tightly and are now generally preferred as safer. Research consistently shows that linear agents leave more gadolinium in the body than macrocyclic agents, likely because gadolinium dissociates more easily from the open-chain structure. This finding guided regulatory decisions in Europe and influenced many U.S. radiology departments to prefer macrocyclic agents for most indications. Some linear agents remain in use for specific purposes, such as liver imaging, where their properties are useful. Patients can ask which agent is planned and why.

What Should I Ask Before a Contrast MRI?

Ask whether contrast is truly needed, which type of agent will be used, your kidney function, and any history of reactions, so you and your doctor can weigh the benefits against the small risks. Is contrast necessary for this scan? Many MRIs are done without contrast. Ask whether contrast will meaningfully change the diagnosis or treatment.

Which agent will be used? Ask whether it is a macrocyclic agent and why the chosen agent is appropriate.

How many contrast scans have I had? If you have had many, mention it, especially if more are planned.

Is my kidney function adequate? People with kidney disease may need special precautions.

Are there alternatives? Ultrasound, CT, or non-contrast MRI may sometimes provide the needed information.

Read the Medication Guide provided before a gadolinium-enhanced MRI, and ask questions about anything unclear. For most patients, the diagnostic benefits of a contrast MRI, when medically indicated, outweigh the uncertain risks of retention.

Pregnancy and Children

Gadolinium crosses the placenta, and guidelines generally recommend avoiding gadolinium contrast during pregnancy unless it is essential for diagnosis. Children may need repeated MRIs for chronic conditions over their lifetimes, so pediatric radiologists pay particular attention to the choice of agent and the necessity of contrast. Parents can ask about these considerations.

Be Wary of Unproven Treatments

Some clinics offer chelation therapy, using drugs that bind metals, to remove retained gadolinium. Chelation can have serious side effects, including kidney damage and dangerous drops in calcium, and its benefit for gadolinium-related symptoms has not been established in controlled trials. Patients with persistent symptoms after MRI should work with physicians to evaluate all possible causes and should approach unproven treatments with caution.

Alternatives to Gadolinium Contrast

For some clinical questions, alternatives to gadolinium-enhanced MRI exist. Non-contrast MRI techniques, such as diffusion-weighted imaging and specialized angiography sequences, can sometimes provide adequate information. Ultrasound, including contrast-enhanced ultrasound with microbubble agents, is useful for certain organs. CT scans with iodine-based contrast are alternatives for some indications, though they involve ionizing radiation and have their own risks, particularly for people with kidney disease or iodine contrast allergies. Researchers are developing new contrast agents, including lower-dose gadolinium agents with higher relaxivity and manganese-based agents, to reduce or avoid gadolinium exposure. The best choice depends on the clinical question, and radiologists can explain trade-offs.

Lower-Dose and Newer Agents

One strategy to reduce gadolinium exposure is using agents that produce stronger image enhancement per unit of gadolinium, allowing lower doses. In recent years, regulators have approved a newer macrocyclic agent designed to be effective at roughly half the usual gadolinium dose. Radiology practices also reduce exposure by using contrast only when it will change care, avoiding repeat scans when possible, and following weight-based dosing. These practices reflect a broader principle in medical imaging: use the lowest exposure that achieves the diagnostic goal.

Who May Be at Higher Risk

Regulators and professional societies have identified groups for whom extra caution is reasonable. People with severe chronic kidney disease or acute kidney injury are at risk of nephrogenic systemic fibrosis, particularly with certain agents, and radiology practices screen kidney function before contrast. People who will need many contrast-enhanced scans over their lifetimes, such as those with multiple sclerosis, certain cancers, or genetic conditions requiring surveillance, accumulate more exposure. Children, whose brains are developing, and pregnant people are also groups for whom necessity and agent choice receive particular attention. For these groups, clinicians may weigh whether contrast is essential for each scan and choose macrocyclic agents.

Evaluating Symptoms After an MRI

People who develop new symptoms after a contrast-enhanced MRI deserve a careful medical evaluation. Some reactions, such as rash, hives, nausea, or, rarely, severe allergic reactions, occur during or shortly after injection and are well recognized. Persistent symptoms such as pain, burning sensations, fatigue, or cognitive changes have many possible causes, including the condition that prompted the MRI. Clinicians can review the patient’s history, perform examinations and tests, and consider whether gadolinium could be involved. Measuring gadolinium in urine can show recent exposure, but levels do not by themselves establish that symptoms are caused by gadolinium. Patients and clinicians can report suspected adverse reactions to the FDA’s MedWatch program, which helps regulators track safety signals.

Why the Norris Case Resonated

The Norris case drew attention because of Chuck Norris’s fame and because it highlighted gaps in knowledge and communication. Many patients receiving contrast had never been told that gadolinium could remain in their bodies, and the discovery of retention in people with normal kidney function was relatively new. The FDA’s requirement for a Medication Guide responded in part to this communication gap, ensuring that patients receive information before their first gadolinium-enhanced scan. Whether or not gadolinium caused Gena Norris’s illness, her experience helped push regulators and the medical community toward greater transparency.

Key Terms

Gadolinium-based contrast agent (GBCA): An injectable drug containing gadolinium used to improve MRI images.

Chelate: A molecule that binds a metal ion; in GBCAs, it holds gadolinium to reduce toxicity.

Linear agent: A GBCA with an open-chain chelate structure.

Macrocyclic agent: A GBCA with a ring-shaped chelate that binds gadolinium more tightly.

Nephrogenic systemic fibrosis (NSF): A rare fibrosing disease linked to gadolinium in people with severe kidney disease.

Medication Guide: FDA-required patient information provided with certain drugs.

The Bottom Line

Gadolinium-based contrast agents help diagnose serious diseases, and for most patients the benefits of a medically necessary contrast MRI outweigh the risks. Research since 2014 has shown that gadolinium can remain in the brain and other tissues, especially with linear agents and repeated doses, prompting European restrictions and a U.S. class warning in 2017. Regulators have not found that retention harms people with normal kidney function, while some patients report persistent symptoms that remain under study. Patients can ask whether contrast is needed, which agent will be used, and what alternatives exist, and should read the Medication Guide before their scan.

Talking With Your Radiologist

Radiologists are physicians who specialize in imaging and are generally available to answer questions about contrast, either before a scan or through the referring physician. Patients concerned about gadolinium can ask to speak with a radiologist about whether contrast is needed for their specific question, which agent is planned, and how their kidney function and prior exposures factor into the decision. Many imaging centers have policies favoring macrocyclic agents and minimizing unnecessary contrast. Bringing a list of prior contrast-enhanced scans can help the team make informed decisions.

The Balance of Benefits and Risks

Every medical test involves trade-offs. A contrast-enhanced MRI can detect a tumor early, guide treatment for multiple sclerosis, or identify an infection requiring urgent care, benefits that can be life-changing. The risks of gadolinium, apart from rare acute reactions and nephrogenic systemic fibrosis in people with severe kidney disease, remain uncertain, with retention documented but harm not established in people with normal kidney function. For most patients, a medically necessary contrast MRI is reasonable. For patients needing many scans, or those with particular concerns, thoughtful choices about necessity and agent selection can reduce exposure while preserving diagnostic benefits.

Common Misconceptions

“Gadolinium is a heavy metal poison given carelessly.” Gadolinium is bound in chelates to reduce toxicity, and its use is regulated and generally reserved for scans where contrast adds diagnostic value.

“All gadolinium leaves the body within a day.” Most is eliminated quickly in people with healthy kidneys, but small amounts can remain in tissues for years.

“Retention proves harm.” Retention is documented, but harm in people with normal kidney function has not been established.

“Chelation therapy safely removes gadolinium.” Chelation has risks and unproven benefits for this purpose.

“Only people with kidney disease face any risk.” NSF primarily affects people with severe kidney disease, but retention occurs in people with normal kidney function too.

Key Facts at a Glance

A 2014 study in Radiology linked increasing brain signal changes to cumulative gadolinium doses, and a 2015 Mayo Clinic autopsy study confirmed gadolinium deposits in the brains of patients with normal kidney function who had at least four contrast MRIs. In July 2017, European regulators suspended several linear agents; in December 2017, the FDA required a class warning about retention and a patient Medication Guide. Nephrogenic systemic fibrosis, linked to gadolinium in people with severe kidney disease in 2006, is now rare with precautions. Chuck and Gena Norris sued 11 companies in 2017 and later abandoned the case.

Research on the long-term significance of retention continues, and patients can expect guidance to evolve as new studies are published.

Further Reading

Patients seeking more information can read the Medication Guide provided with gadolinium contrast, the European Medicines Agency’s review of gadolinium-containing contrast agents, and patient information from radiology professional societies. Research articles in journals such as Radiology continue to report on retention and safety. When reading online information, it helps to distinguish between established findings, such as retention and nephrogenic systemic fibrosis, and claims that remain unproven.

Discussing what you read with a radiologist or referring physician can help put new studies or online claims into context for your own situation.

For Parents

Parents whose children need MRI scans can ask whether contrast is necessary, which agent will be used, and whether sedation is required, since young children often need sedation to stay still. Pediatric radiology departments typically use macrocyclic agents and minimize contrast use. For children with chronic conditions requiring repeated imaging, families can discuss a long-term imaging plan that balances diagnostic needs with cumulative exposure.

Global Perspective

Regulators worldwide reached broadly similar conclusions after reviewing gadolinium retention. Japan’s regulator requested labeling changes, European regulators restricted linear agents, and other countries updated product information. Professional radiology societies issued guidance emphasizing appropriate use, preference for macrocyclic agents, and attention to kidney function. These coordinated responses reflect a shared approach: acknowledging uncertainty, taking precautionary steps where they are low-cost, and continuing to study long-term effects.

For anyone weighing a contrast-enhanced MRI, the most useful steps are simple: confirm that contrast is necessary, ask which agent will be used, share your history of prior scans and kidney health, and read the Medication Guide. These steps reflect what is known today and help patients participate in decisions about their own care.

Medical knowledge about gadolinium will continue to develop, and patients who stay informed and ask questions will be best positioned to benefit from new findings and newer agents as they become available.

Questions about specific symptoms or past exposures should always be discussed with a qualified clinician who can review the full medical history.

Patients can also request copies of their imaging reports, which typically note whether contrast was used and which agent was given.

Summary for Patients

Gadolinium contrast improves the accuracy of many MRI scans and is generally safe for people with healthy kidneys. Small amounts can remain in the body, especially with linear agents, but harm from retention has not been established. Ask whether contrast is necessary, which agent is planned, and share your history of contrast scans. People with severe kidney disease need special precautions. Report persistent new symptoms to your doctor for careful evaluation.

These steps take only a few minutes before a scan but can provide meaningful peace of mind and help ensure that contrast is used only when it truly adds value to diagnosis and care. Patients who need frequent imaging may find it helpful to keep a simple personal record of each scan, including dates and whether contrast was used.

That record can be shared with any new clinician or imaging center to support informed decisions about future scans and to avoid unnecessary repeat contrast.

Gadolinium During Pregnancy

Gadolinium crosses the placenta, and the fetal effects of exposure have been difficult to study. A 2016 Ontario study in JAMA by Joel Ray and colleagues linked health records for more than a million births and found that gadolinium-enhanced MRI at any time during pregnancy was associated with a higher risk of a broad group of rheumatological, inflammatory, or infiltrative skin conditions in children and of stillbirth or neonatal death, while non-contrast MRI in the first trimester was not associated with harm. The number of exposed pregnancies was small and the findings are observational, but they support guidelines recommending that gadolinium be avoided during pregnancy unless essential.

Frequently Asked Questions

Is gadolinium contrast dye safe?

For most people, yes. Gadolinium-based contrast agents are used in millions of MRI scans each year and are generally considered safe. Small amounts can remain in the body for a time, and rare serious reactions occur, but for the large majority of patients the diagnostic benefits far outweigh the risks, especially with newer, more stable agents.

Does gadolinium stay in your body after an MRI?

Yes, to a degree. Studies since 2017 found that small amounts of gadolinium can be retained in the brain, bones, and other tissues after contrast MRI scans, particularly with older “linear” agents. For people with normal kidney function, this retention has not been clearly linked to health problems, and the body clears most of it over time.

What is nephrogenic systemic fibrosis?

Nephrogenic systemic fibrosis is a rare but serious condition causing thickening and hardening of the skin and tissues, linked to gadolinium contrast in people with severe kidney disease. It is the one well-established serious harm from gadolinium. Screening patients’ kidney function and using safer agents has made it very rare today.

Is “gadolinium deposition disease” a real diagnosis?

It is debated. Some patients with normal kidneys report symptoms such as pain, fatigue, and cognitive problems they attribute to retained gadolinium, which they call “gadolinium deposition disease.” It is not an officially recognized medical diagnosis, and researchers have not established that retained gadolinium causes these symptoms, though investigation continues.

Should I avoid contrast MRIs because of gadolinium?

Not routinely. For most people, contrast-enhanced MRI provides important diagnostic information that outweighs the small risks of gadolinium. You can ask whether contrast is necessary, which agent will be used, and about your kidney function. People with severe kidney disease or prior reactions should discuss alternatives with their doctor, but healthy patients generally need not refuse contrast.

References

1. Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2014;270(3):834–841. PMID 24475844
2. McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. Radiology. 2015;275(3):772–782. PMID 25742194
3. Grobner T. Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrology Dialysis Transplantation. 2006;21(4):1104–1108. PMID 16431890
4. European Medicines Agency. Gadolinium-containing contrast agents: referral. ema.europa.eu
5. Bangor Daily News (Washington Post). Chuck Norris claims wife was poisoned during MRI scans, sues for $10 million. November 9, 2017. bangordailynews.com
6. HarrisMartin. Actor Chuck Norris, Wife, Abandon Gadolinium-Based Contrast Agent Lawsuit. harrismartin.com
7. Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. Association Between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes. JAMA. 2016;316(9):952–961. PMID 27599330

Last updated: October 6, 2026